Advances in the treatment of aggessive lymphomas. Part 3 of a 3-part series: Advances in the treatment of hematologic maliganancies

Thomas Matthew Habermann, Craig H. Moskowitz, Michael Pfreundschuh

Research output: Contribution to journalArticle

Abstract

Despite recent declines in overall cancer mortality rates in the United State, the incidence and mortality rates for lymphoma has been increasing. For patients with high-risk diffuse large B-cell lymphoma, treatment options currently being explored include various combinations of the monoclonal antibody rituximab plus chemotherapy, as well as high-dose and dose-dense chemotherapy followed by transplantation. For mantle cell lymphoma, researchers are evaluating bortezomib, tositumomab plus iodine tositumomab, the cyclin D1 regulator temsirolimus, and allogeneic stem cell transplantation. Because mantle cell lymphoma is often chemotherapy-sensitive, many clinical trails have focused on determining the optimal treatment strategy following an initial response with chemotherapy. Strategies being investigated for these patients include autologous stem cell transplantation and interferon-α treatment. For the treatment of mature T-cell lymphomas, a standard-of-treatment has not been established and progress has been hampered by a lack of randomized clinical trials. However, several treatments are currently being evaluated, including primary allogeneic transplantation, alternative chemotherapy regimens, and alemtuzumab. In the area of immunodeficiency-associated lymphosproliferative disorders, a number of recent studies have focused on human immunodeficiency virus-related non-Hodgkin lymphoma. Outcomes for these patients have improved significantly with the introduction of highly active antiretroviral therapy. Finally, (or posttransplantation lymphoproliferative disorders, minimizing immunosuppression has been a hallmark of treatment strategies, and rituximab has demonstrated activity in these patients.

Original languageEnglish (US)
JournalClinical Advances in Hematology and Oncology
Volume3
Issue number11 SUPPL. 11
StatePublished - Nov 2005

Fingerprint

Lymphoma
Drug Therapy
Mantle-Cell Lymphoma
Stem Cell Transplantation
Therapeutics
Lymphoproliferative Disorders
Lymphoma, Large B-Cell, Diffuse
Mortality
T-Cell Lymphoma
Cyclin D1
Homologous Transplantation
Highly Active Antiretroviral Therapy
Iodine
Non-Hodgkin's Lymphoma
Immunosuppression
Interferons
Randomized Controlled Trials
Transplantation
Monoclonal Antibodies
Research Personnel

Keywords

  • Aggressive lymphoma
  • Diffuse large B-cell lymphoma
  • Mantle cell lymphoma
  • Mature T-cell lymphoma
  • Monoclonal antibodies
  • NK/T-cell lymphoma
  • Posttransplantation lymphoproliferative disease
  • Transplantation

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Advances in the treatment of aggessive lymphomas. Part 3 of a 3-part series : Advances in the treatment of hematologic maliganancies. / Habermann, Thomas Matthew; Moskowitz, Craig H.; Pfreundschuh, Michael.

In: Clinical Advances in Hematology and Oncology, Vol. 3, No. 11 SUPPL. 11, 11.2005.

Research output: Contribution to journalArticle

@article{38719901fcfe4ab2920f9b94adf39a0d,
title = "Advances in the treatment of aggessive lymphomas. Part 3 of a 3-part series: Advances in the treatment of hematologic maliganancies",
abstract = "Despite recent declines in overall cancer mortality rates in the United State, the incidence and mortality rates for lymphoma has been increasing. For patients with high-risk diffuse large B-cell lymphoma, treatment options currently being explored include various combinations of the monoclonal antibody rituximab plus chemotherapy, as well as high-dose and dose-dense chemotherapy followed by transplantation. For mantle cell lymphoma, researchers are evaluating bortezomib, tositumomab plus iodine tositumomab, the cyclin D1 regulator temsirolimus, and allogeneic stem cell transplantation. Because mantle cell lymphoma is often chemotherapy-sensitive, many clinical trails have focused on determining the optimal treatment strategy following an initial response with chemotherapy. Strategies being investigated for these patients include autologous stem cell transplantation and interferon-α treatment. For the treatment of mature T-cell lymphomas, a standard-of-treatment has not been established and progress has been hampered by a lack of randomized clinical trials. However, several treatments are currently being evaluated, including primary allogeneic transplantation, alternative chemotherapy regimens, and alemtuzumab. In the area of immunodeficiency-associated lymphosproliferative disorders, a number of recent studies have focused on human immunodeficiency virus-related non-Hodgkin lymphoma. Outcomes for these patients have improved significantly with the introduction of highly active antiretroviral therapy. Finally, (or posttransplantation lymphoproliferative disorders, minimizing immunosuppression has been a hallmark of treatment strategies, and rituximab has demonstrated activity in these patients.",
keywords = "Aggressive lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma, Mature T-cell lymphoma, Monoclonal antibodies, NK/T-cell lymphoma, Posttransplantation lymphoproliferative disease, Transplantation",
author = "Habermann, {Thomas Matthew} and Moskowitz, {Craig H.} and Michael Pfreundschuh",
year = "2005",
month = "11",
language = "English (US)",
volume = "3",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "11 SUPPL. 11",

}

TY - JOUR

T1 - Advances in the treatment of aggessive lymphomas. Part 3 of a 3-part series

T2 - Advances in the treatment of hematologic maliganancies

AU - Habermann, Thomas Matthew

AU - Moskowitz, Craig H.

AU - Pfreundschuh, Michael

PY - 2005/11

Y1 - 2005/11

N2 - Despite recent declines in overall cancer mortality rates in the United State, the incidence and mortality rates for lymphoma has been increasing. For patients with high-risk diffuse large B-cell lymphoma, treatment options currently being explored include various combinations of the monoclonal antibody rituximab plus chemotherapy, as well as high-dose and dose-dense chemotherapy followed by transplantation. For mantle cell lymphoma, researchers are evaluating bortezomib, tositumomab plus iodine tositumomab, the cyclin D1 regulator temsirolimus, and allogeneic stem cell transplantation. Because mantle cell lymphoma is often chemotherapy-sensitive, many clinical trails have focused on determining the optimal treatment strategy following an initial response with chemotherapy. Strategies being investigated for these patients include autologous stem cell transplantation and interferon-α treatment. For the treatment of mature T-cell lymphomas, a standard-of-treatment has not been established and progress has been hampered by a lack of randomized clinical trials. However, several treatments are currently being evaluated, including primary allogeneic transplantation, alternative chemotherapy regimens, and alemtuzumab. In the area of immunodeficiency-associated lymphosproliferative disorders, a number of recent studies have focused on human immunodeficiency virus-related non-Hodgkin lymphoma. Outcomes for these patients have improved significantly with the introduction of highly active antiretroviral therapy. Finally, (or posttransplantation lymphoproliferative disorders, minimizing immunosuppression has been a hallmark of treatment strategies, and rituximab has demonstrated activity in these patients.

AB - Despite recent declines in overall cancer mortality rates in the United State, the incidence and mortality rates for lymphoma has been increasing. For patients with high-risk diffuse large B-cell lymphoma, treatment options currently being explored include various combinations of the monoclonal antibody rituximab plus chemotherapy, as well as high-dose and dose-dense chemotherapy followed by transplantation. For mantle cell lymphoma, researchers are evaluating bortezomib, tositumomab plus iodine tositumomab, the cyclin D1 regulator temsirolimus, and allogeneic stem cell transplantation. Because mantle cell lymphoma is often chemotherapy-sensitive, many clinical trails have focused on determining the optimal treatment strategy following an initial response with chemotherapy. Strategies being investigated for these patients include autologous stem cell transplantation and interferon-α treatment. For the treatment of mature T-cell lymphomas, a standard-of-treatment has not been established and progress has been hampered by a lack of randomized clinical trials. However, several treatments are currently being evaluated, including primary allogeneic transplantation, alternative chemotherapy regimens, and alemtuzumab. In the area of immunodeficiency-associated lymphosproliferative disorders, a number of recent studies have focused on human immunodeficiency virus-related non-Hodgkin lymphoma. Outcomes for these patients have improved significantly with the introduction of highly active antiretroviral therapy. Finally, (or posttransplantation lymphoproliferative disorders, minimizing immunosuppression has been a hallmark of treatment strategies, and rituximab has demonstrated activity in these patients.

KW - Aggressive lymphoma

KW - Diffuse large B-cell lymphoma

KW - Mantle cell lymphoma

KW - Mature T-cell lymphoma

KW - Monoclonal antibodies

KW - NK/T-cell lymphoma

KW - Posttransplantation lymphoproliferative disease

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=35848970568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848970568&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:35848970568

VL - 3

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 11 SUPPL. 11

ER -